Air-Liquid Interface Cell Exposures to Nanoparticle Aerosols

Book cover
Biomedical Nanotechnology pp 301–313Cite as

Air–Liquid Interface Cell Exposures to Nanoparticle Aerosols
Nastassja A. Lewinski, Nathan J. Liu, Akrivi Asimakopoulou, Eleni Papaioannou, Athanasios Konstandopoulos & Michael Riediker
Protocol
First Online: 26 February 2017
2658 Accesses

3 Citations

Part of the Methods in Molecular Biology book series (MIMB,volume 1570)

Abstract
The field of nanomedicine is steadily growing and several nanomedicines are currently approved for clinical use with even more in the pipeline. Yet, while the use of nanotechnology to improve targeted drug delivery to the lungs has received some attention, the use of nanoparticles for inhalation drug delivery has not yet resulted in successful translation to market as compared to intravenous drug delivery. The reasons behind the lack of inhaled nanomedicines approved for clinical use or under preclinical development are unclear, but challenges related to safety are likely to contribute. Although inhalation toxicology studies often begin using animal models, there has been an increase in the development and use of in vitro air–liquid interface (ALI) exposure systems for toxicity testing of engineered nanoparticle aerosols, which will be useful for rapid testing of candidate substances and formulations. This chapter describes an ALI cell exposure assay for measuring toxicological effects, specifically cell viability and oxidative stress, resulting from exposure to aerosols containing nanoparticles.